SciSparc announced that MitoCareX Bio has validated the potential significant involvement of its target SLC25 carrier protein, using Non-Small Cell Lung Cancer cells with diverse genetic backgrounds. MitoCareX demonstrated the discovery by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors. Previously, MitoCareX Bio had virtually screened millions of small molecules by using its computationally advanced drug discovery platform, which includes its proprietary MITOLINE algorithm. Following the successful virtual screening campaign, MitoCareX identified several small molecules that could potentially be used for anti-cancer treatments. By utilizing the extensive virtual data generated, MitoCareX is working towards creating a predictive AI model. This model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer small molecule scaffolds that target its SLC25 protein of interest.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- Here’s What You Missed in Cannabis, Psychedelics This Week
- SciSparc Eyes $6M Deal for Pain Treatment License
- SciSparc signs LOI for exclusive global out-licensing of pain treatment for $6M
- SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
- SciSparc Ltd. Faces Nasdaq Delisting Over Bid Price